Ari Melnick - Publications

Weill Cornell Medicine 
Cancer Epigenetics

209 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Zee BM, Poels KE, Yao CH, Kawabata KC, Wu G, Duy C, Jacobus WD, Senior E, Endress JE, Jambhekar A, Lovitch SB, Ma J, Dhall A, Harris IS, Blanco MA, ... ... Melnick A, et al. Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. Iscience. 24: 102651. PMID 34151238 DOI: 10.1016/j.isci.2021.102651  0.8
2021 Carrasco-Leon A, Ezponda T, Meydan C, Valcárcel LV, Ordoñez R, Kulis M, Garate L, Miranda E, Segura V, Guruceaga E, Vilas-Zornoza A, Alignani D, Pascual M, Amundarain A, Castro-Labrador L, ... ... Melnick A, et al. Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma. Leukemia. PMID 33597729 DOI: 10.1038/s41375-021-01147-y  0.36
2020 Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J, Phillip JM, Elemento O, Scott DW, Béguelin W, Licht JD, ... ... Melnick AM, et al. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature. PMID 33299181 DOI: 10.1038/s41586-020-3017-y  0.8
2020 Ordonez R, Kulis M, Russinol N, Chapaprieta V, Carrasco-Leon A, Garcia-Torre B, Charampopoulou S, Clot G, Beekman R, Meydan C, Duran-Ferrer M, Verdaguer-Dot N, Vilarrasa-Blasi R, Soler-Vila P, Garate L, ... ... Melnick A, et al. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Research. PMID 32820006 DOI: 10.1101/Gr.265520.120  0.8
2020 Fabre MS, Stanton NM, Slatter TL, Lee S, Senanayake D, Gordon RMA, Castro ML, Rowe MR, Taha A, Royds JA, Hung N, Melnick AM, McConnell MJ. The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy. Plos One. 15: e0231470. PMID 32320427 DOI: 10.1371/journal.pone.0231470  0.44
2019 Fernando TM, Marullo R, Pera Gresely B, Phillip JM, Yang SN, Lundell-Smith G, Torregroza I, Ahn H, Evans T, Gyorffy B, Prive GG, Hirano M, Melnick AM, Cerchietti L. BCL6 evolved to enable stress tolerance in vertebrates and is broadly required by cancer cells to adapt to stress. Cancer Discovery. PMID 30777872 DOI: 10.1158/2159-8290.Cd-17-1444  0.32
2019 Carrasco A, Ezponda T, Meydan C, Valcárcel LV, Ordoñez R, Kulis M, Garate L, Miranda E, Segura V, Guruceaga E, Vilas-Zornoza A, Alignani D, Castro L, Pascual M, Amundarain A, ... ... Melnick AM, et al. Characterization of Complete Lncrnas Transcriptome Reveals Expression of Lncrnas As a Prognostic Factor and Linc-Smilo As a Potential Therapeutic Target in Multiple Myeloma Blood. 134: 4323-4323. DOI: 10.1182/Blood-2019-123008  0.36
2017 Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SN, Oswald E, Graham CW, Jiang Y, Hatzi K, Agirre X, Perkey E, ... ... Melnick A, et al. BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer Discovery. PMID 28232365 DOI: 10.1158/2159-8290.Cd-16-1189  0.36
2016 Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre Ena X, Teater M, Meydan C, Li Z, Poloway D, Wang S, ... ... Melnick AM, et al. CREBBP Inactivation Promotes the Development of HDAC3 Dependent Lymphomas. Cancer Discovery. PMID 27733359 DOI: 10.1158/2159-8290.Cd-16-0975  0.44
2016 Béguelin W, Teater M, Gearhart MD, Calvo Fernández MT, Goldstein RL, Cárdenas MG, Hatzi K, Rosen M, Shen H, Corcoran CM, Hamline MY, Gascoyne RD, Levine RL, Abdel-Wahab O, Licht JD, ... ... Melnick AM, et al. EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer Cell. 30: 197-213. PMID 27505670 DOI: 10.1016/J.Ccell.2016.07.006  0.8
2016 Fiskus W, Coothankandaswamy V, Chen J, Ma H, Ha K, Saenz DT, Krieger SS, Mill CP, Sun B, Huang P, Mumm JS, Melnick A, Bhalla KN. SIRT2 deacetylates and inhibits the peroxidase activity of peroxiredoxin-1 to sensitize breast cancer cells to oxidant stress inducing agents. Cancer Research. PMID 27503926 DOI: 10.1158/0008-5472.Can-16-0126  0.44
2016 Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang SN, Cohen J, Shaknovich R, Vanommeslaeghe K, Cheng H, Liang D, Cho HJ, ... ... Melnick AM, et al. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. The Journal of Clinical Investigation. PMID 27482887 DOI: 10.1172/Jci85795  0.44
2016 Han D, Lu X, Shih AH, Nie J, You Q, Xu MM, Melnick AM, Levine RL, He C. A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations. Molecular Cell. PMID 27477909 DOI: 10.1016/J.Molcel.2016.06.028  0.44
2016 Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, ... ... Melnick AM, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine. PMID 27322744 DOI: 10.1038/Nm.4125  0.44
2016 Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martin-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, ... ... Melnick AM, et al. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. Nature Communications. 7: 11889. PMID 27297662 DOI: 10.1038/ncomms11889  0.36
2016 Li S, Mason C, Melnick A. Genetic and epigenetic heterogeneity in acute myeloid leukemia. Current Opinion in Genetics & Development. 36: 100-106. PMID 27162099 DOI: 10.1016/J.Gde.2016.03.011  0.44
2016 Jiang Y, Dominguez PM, Melnick A. The many layers of epigenetic dysfunction in B-cell lymphomas. Current Opinion in Hematology. PMID 27055146 DOI: 10.1097/Moh.0000000000000249  0.44
2016 Meyer SE, Qin T, Muench DE, Masuda K, Venkatasubramanian M, Orr E, Suarez L, Gore SD, Delwel R, Paietta E, Tallman MS, Fernandez H, Melnick A, Le Beau MM, Kogan S, et al. Dnmt3a haploinsufficiency transforms Flt3-ITD myeloproliferative disease into a rapid, spontaneous, and fully-penetrant acute myeloid leukemia. Cancer Discovery. PMID 27016502 DOI: 10.1158/2159-8290.Cd-16-0008  0.44
2016 Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, et al. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nature Medicine. PMID 26974310 DOI: 10.1038/Nm.4062  0.44
2016 Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, et al. Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. PMID 26958840 DOI: 10.1038/Nature16997  0.44
2015 Dupont T, Yang S, Patel J, Hatzi K, Malik A, Tam W, Martin P, Leonard J, Melnick A, Cerchietti L. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget. PMID 26657288 DOI: 10.18632/Oncotarget.6513  0.44
2015 Zong H, Gozman A, Caldas-Lopes E, Taldone T, Sturgill E, Brennan S, Ochiana SO, Gomes-DaGama EM, Sen S, Rodina A, Koren J, Becker MW, Rudin CM, Melnick A, Levine RL, et al. A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell Reports. PMID 26628369 DOI: 10.1016/J.Celrep.2015.10.073  0.44
2015 Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL, Patel J, Taldone T, Chiosis G, Ladetto M, Ghione P, ... ... Melnick A, et al. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood. PMID 26603836 DOI: 10.1182/Blood-2015-05-645069  0.44
2015 Huang C, Melnick A. Mechanisms of action of BCL6 during germinal center B cell development. Science China. Life Sciences. PMID 26566802 DOI: 10.1007/S11427-015-4919-Z  0.44
2015 Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, Cerchietti L, Melnick A. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. The Journal of Clinical Investigation. 2015. PMID 26529251 DOI: 10.1172/Jci80714  0.44
2015 Tian YF, Ahn H, Schneider RS, Yang SN, Roman-Gonzalez L, Melnick AM, Cerchietti L, Singh A. Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. Biomaterials. 73: 110-119. PMID 26406451 DOI: 10.1016/j.biomaterials.2015.09.007  0.44
2015 Dominguez PM, Teater M, Chambwe N, Kormaksson M, Redmond D, Ishii J, Vuong B, Chaudhuri J, Melnick A, Vasanthakumar A, Godley LA, Papavasiliou FN, Elemento O, Shaknovich R. DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. Cell Reports. 12: 2086-98. PMID 26365193 DOI: 10.1016/J.Celrep.2015.08.036  0.44
2015 Noh KM, Wang H, Kim HR, Wenderski W, Fang F, Li CH, Dewell S, Hughes SH, Melnick AM, Patel DJ, Li H, Allis CD. Engineering of a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and Phenotypic Features of Mouse ESCs. Molecular Cell. 59: 89-103. PMID 26073541 DOI: 10.1016/J.Molcel.2015.05.017  0.44
2015 Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, ... ... Melnick A, et al. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell. 28: 114-28. PMID 26073130 DOI: 10.1016/J.Ccell.2015.05.008  0.44
2015 Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R, Melnick AM, Inghirami GG, Tam W, Elemento O. Epigenomic evolution in diffuse large B-cell lymphomas. Nature Communications. 6: 6921. PMID 25891015 DOI: 10.1182/Blood.V122.21.634.634  0.44
2015 Shih AH, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, ... ... Melnick A, et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell. 27: 502-15. PMID 25873173 DOI: 10.1016/J.Ccell.2015.03.009  0.44
2015 Hatzi K, Nance JP, Kroenke MA, Bothwell M, Haddad EK, Melnick A, Crotty S. BCL6 orchestrates Tfh cell differentiation via multiple distinct mechanisms. The Journal of Experimental Medicine. 212: 539-53. PMID 25824819 DOI: 10.1084/Jem.20141380  0.44
2015 Weinstock DM, Dalla-Favera R, Gascoyne RD, Leonard JP, Levy R, Lossos IS, Melnick AM, Nowakowski GS, Press OW, Savage KJ, Shipp MA, Staudt LM. A roadmap for discovery and translation in lymphoma. Blood. 125: 2175-7. PMID 25814490 DOI: 10.1182/Blood-2015-01-623777  0.44
2015 Jiang Y, Melnick A. The epigenetic basis of diffuse large B-cell lymphoma. Seminars in Hematology. 52: 86-96. PMID 25805588 DOI: 10.1053/J.Seminhematol.2015.01.003  0.44
2015 Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 521: 357-61. PMID 25799995 DOI: 10.1038/Nature14231  0.44
2015 Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, ... ... Melnick A, et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 27: 409-25. PMID 25759025 DOI: 10.1016/J.Ccell.2015.02.003  0.44
2015 Buchner M, Park E, Geng H, Klemm L, Flach J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, Raychaudhuri P, Müschen M. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nature Communications. 6: 6471. PMID 25753524 DOI: 10.1038/Ncomms7471  0.44
2015 Garrett-Bakelman FE, Sheridan CK, Kacmarczyk TJ, Ishii J, Betel D, Alonso A, Mason CE, Figueroa ME, Melnick AM. Enhanced reduced representation bisulfite sequencing for assessment of DNA methylation at base pair resolution. Journal of Visualized Experiments : Jove. e52246. PMID 25742437 DOI: 10.3791/52246  0.44
2015 Park SM, Gönen M, Vu L, Minuesa G, Tivnan P, Barlowe TS, Taggart J, Lu Y, Deering RP, Hacohen N, Figueroa ME, Paietta E, Fernandez HF, Tallman MS, Melnick A, et al. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. The Journal of Clinical Investigation. 125: 1286-98. PMID 25664853 DOI: 10.1172/Jci78440  0.44
2015 Chen L, Chen W, Mysliwski M, Serio J, Ropa J, Abulwerdi FA, Chan RJ, Patel JP, Tallman MS, Paietta E, Melnick A, Levine RL, Abdel-Wahab O, Nikolovska-Coleska Z, Muntean AG. Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. Leukemia. 29: 1290-300. PMID 25650089 DOI: 10.1038/Leu.2015.18  0.44
2015 Agirre X, Castellano G, Pascual M, Heath S, Kulis M, Segura V, Bergmann A, Esteve A, Merkel A, Raineri E, Agueda L, Blanc J, Richardson D, Clarke L, Datta A, ... ... Melnick A, et al. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Research. 25: 478-87. PMID 25644835 DOI: 10.1016/J.Clml.2015.07.243  0.44
2015 Van der Meulen J, Sanghvi V, Mavrakis K, Durinck K, Fang F, Matthijssens F, Rondou P, Rosen M, Pieters T, Vandenberghe P, Delabesse E, Lammens T, De Moerloose B, Menten B, Van Roy N, ... ... Melnick AM, et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood. 125: 13-21. PMID 25320243 DOI: 10.1182/blood-2014-05-577270  0.44
2015 Kuo PY, Leshchenko VV, Fazzari MJ, Perumal D, Gellen T, He T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh KS, Goy A, Yang DT, Chan WC, ... ... Melnick AM, et al. High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma. Oncogene. 34: 1231-40. PMID 24681958 DOI: 10.1038/Onc.2014.44  0.44
2015 Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, Elemento O, Cerchietti L, Melnick A, Frank DA. The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene. 34: 1073-82. PMID 24662818 DOI: 10.1038/Onc.2014.61  0.44
2015 Kraljacic-Culkjovic B, Fernando T, Goldstein R, Mctavish C, Patel J, Yang S, Tabbo F, Melnick A, Inghirami G, Borden KL, Cerchietti L. Abstract B12: EIF4E deregulation drives simultaneous expression of B-cell lymphoma oncogenes. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-B12  0.32
2015 Boss IW, Melnick AM. VII. Are lymphomas driven by epigenetic lesions? Hematological Oncology. 33: 42-45. DOI: 10.1002/hon.2215  0.44
2014 Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, Li Y, Ahn J, Abdel-Wahab O, Shih A, Lu C, Ward PS, Tsai JJ, Hricik T, Tosello V, ... ... Melnick A, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Reports. 9: 1841-55. PMID 25482556 DOI: 10.1016/J.Celrep.2014.11.004  0.44
2014 Patel RG, Purwada A, Cerchietti L, Inghirami G, Melnick A, Gaharwar AK, Singh A. Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications. Cellular and Molecular Bioengineering. 7: 394-408. PMID 25328548 DOI: 10.1007/S12195-014-0353-8  0.44
2014 Li S, Garrett-Bakelman F, Perl AE, Luger SM, Zhang C, To BL, Lewis ID, Brown AL, D'Andrea RJ, Ross ME, Levine R, Carroll M, Melnick A, Mason CE. Dynamic evolution of clonal epialleles revealed by methclone. Genome Biology. 15: 472. PMID 25260792 DOI: 10.1186/S13059-014-0472-5  0.44
2014 Huang C, Gonzalez DG, Cote CM, Jiang Y, Hatzi K, Teater M, Dai K, Hla T, Haberman AM, Melnick A. The BCL6 RD2 domain governs commitment of activated B cells to form germinal centers. Cell Reports. 8: 1497-508. PMID 25176650 DOI: 10.1016/J.Celrep.2014.07.059  0.44
2014 Jiang Y, Redmond D, Nie K, Eng KW, Clozel T, Martin P, Tan LH, Melnick AM, Tam W, Elemento O. Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biology. 15: 432. PMID 25123191 DOI: 10.1186/s13059-014-0432-0  0.44
2014 Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 5: 5637-50. PMID 25026298 DOI: 10.18632/Oncotarget.2154  0.44
2014 Rodina A, Taldone T, Kang Y, Patel PD, Koren J, Yan P, DaGama Gomes EM, Yang C, Patel MR, Shrestha L, Ochiana SO, Santarossa C, Maharaj R, Gozman A, Cox MB, ... ... Melnick A, et al. Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. Acs Chemical Biology. 9: 1698-705. PMID 24934503 DOI: 10.1021/Cb500256U  0.44
2014 Green MR, Vicente-Dueñas C, Romero-Camarero I, Long Liu C, Dai B, González-Herrero I, García-Ramírez I, Alonso-Escudero E, Iqbal J, Chan WC, Campos-Sanchez E, Orfao A, Pintado B, Flores T, Blanco O, ... ... Melnick A, et al. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nature Communications. 5: 3904. PMID 24887457 DOI: 10.1038/Ncomms4904  0.44
2014 Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, Hu W, Beguelin W, Monette S, Duy C, Rampal R, Telis L, Patel M, Kim MK, Huberman K, ... ... Melnick AM, et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Science Translational Medicine. 6: 238ra71. PMID 24871132 DOI: 10.1126/Scitranslmed.3008004  0.44
2014 Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P, Müschen M. Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 111: E2219-28. PMID 24821775 DOI: 10.1073/Pnas.1400958111  0.44
2014 Kemp CJ, Moore JM, Moser R, Bernard B, Teater M, Smith LE, Rabaia NA, Gurley KE, Guinney J, Busch SE, Shaknovich R, Lobanenkov VV, Liggitt D, Shmulevich I, Melnick A, et al. CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell Reports. 7: 1020-9. PMID 24794443 DOI: 10.1016/J.Celrep.2014.04.004  0.44
2014 Hatzi K, Melnick A. Breaking bad in the germinal center: How deregulation of BCL6 contributes to lymphomagenesis Trends in Molecular Medicine. 20: 343-352. PMID 24698494 DOI: 10.1016/J.Molmed.2014.03.001  0.44
2014 Taskesen E, Havermans M, van Lom K, Sanders MA, van Norden Y, Bindels E, Hoogenboezem R, Reinders MJ, Figueroa ME, Valk PJ, Löwenberg B, Melnick A, Delwel R. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. Blood. 123: 3327-35. PMID 24668493 DOI: 10.1182/Blood-2013-07-512855  0.44
2014 Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabrilove J, Erba HP, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1242-8. PMID 24663049 DOI: 10.1200/Jco.2013.50.3102  0.44
2014 Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, Chauhan L, Rao R, Gunewardena S, Schorno K, Austin CP, Maddocks K, Byrd J, Melnick A, Huang P, et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Research. 74: 2520-32. PMID 24599128 DOI: 10.1158/0008-5472.Can-13-2033  0.44
2014 Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat TD, Okoye-Okafor UC, Todorova TI, Greally JM, Levine RL, Melnick A, Verma A, Steidl U. HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. The Journal of Clinical Investigation. 124: 1158-67. PMID 24487588 DOI: 10.1172/Jci71264  0.44
2014 Chambwe N, Kormaksson M, Geng H, De S, Michor F, Johnson NA, Morin RD, Scott DW, Godley LA, Gascoyne RD, Melnick A, Campagne F, Shaknovich R. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 123: 1699-708. PMID 24385541 DOI: 10.1182/Blood-2013-07-509885  0.44
2014 Huang C, Geng H, Boss I, Wang L, Melnick A. Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation Blood. 123: 1012-1020. PMID 24277074 DOI: 10.1182/Blood-2013-07-518605  0.44
2014 Oyer JA, Huang X, Zheng Y, Shim J, Ezponda T, Carpenter Z, Allegretta M, Okot-Kotber CI, Patel JP, Melnick A, Levine RL, Ferrando A, Mackerell AD, Kelleher NL, Licht JD, et al. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia. 28: 198-201. PMID 23823660 DOI: 10.1038/Leu.2013.204  0.44
2014 Agirre X, Castellano G, Pascual M, Kulis M, Segura V, Bergmann A, Esteve A, Merkel A, Raineri E, Agueda L, Blanc J, Richardson D, Clarke L, Russiñol N, Queirós AC, ... ... Melnick AM, et al. Whole-genome epigenomic analysis in multiple myeloma reveals DNA hypermethylation of b-cell specific enhancers Blood. 124: 2032-2032. DOI: 10.1182/Blood.V124.21.2032.2032  0.36
2013 Vu LP, Perna F, Wang L, Voza F, Figueroa ME, Tempst P, Erdjument-Bromage H, Gao R, Chen S, Paietta E, Deblasio T, Melnick A, Liu Y, Zhao X, Nimer SD. PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex. Cell Reports. 5: 1625-38. PMID 24332853 DOI: 10.1016/J.Celrep.2013.11.025  0.44
2013 Di Ruscio A, Ebralidze AK, Benoukraf T, Amabile G, Goff LA, Terragni J, Figueroa ME, De Figueiredo Pontes LL, Alberich-Jorda M, Zhang P, Wu M, D'Alò F, Melnick A, Leone G, Ebralidze KK, et al. DNMT1-interacting RNAs block gene-specific DNA methylation. Nature. 503: 371-6. PMID 24107992 DOI: 10.1038/Nature12598  0.44
2013 Qiao Q, Yang C, Zheng C, Fontán L, David L, Yu X, Bracken C, Rosen M, Melnick A, Egelman EH, Wu H. Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly. Molecular Cell. 51: 766-79. PMID 24074955 DOI: 10.1016/J.Molcel.2013.08.032  0.44
2013 Lu C, Venneti S, Akalin A, Fang F, Ward PS, Dematteo RG, Intlekofer AM, Chen C, Ye J, Hameed M, Nafa K, Agaram NP, Cross JR, Khanin R, Mason CE, ... ... Melnick A, et al. Induction of sarcomas by mutant IDH2. Genes & Development. 27: 1986-98. PMID 24065766 DOI: 10.1101/Gad.226753.113  0.44
2013 Lai AY, Mav D, Shah R, Grimm SA, Phadke D, Hatzi K, Melnick A, Geigerman C, Sobol SE, Jaye DL, Wade PA. DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation. Genome Research. 23: 2030-41. PMID 24013550 DOI: 10.1101/Gr.155473.113  0.44
2013 Fontán L, Melnick A. Molecular pathways: Targeting MALT1 paracaspase activity in lymphoma Clinical Cancer Research. 19: 6662-6668. PMID 24004675 DOI: 10.1158/1078-0432.Ccr-12-3869  0.44
2013 Cerchietti L, Melnick A. Targeting BCL6 in diffuse large B-cell lymphoma: What does this mean for the future treatment? Expert Review of Hematology. 6: 343-345. PMID 23991920 DOI: 10.1586/17474086.2013.826928  0.44
2013 Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, ... ... Melnick A, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discovery. 3: 1002-19. PMID 23955273 DOI: 10.1158/2159-8290.Cd-13-0117  0.44
2013 Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R, Melnick A, Cerchietti L, Chiosis G, Wang YL, Cesarman E. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 122: 2837-47. PMID 23943653 DOI: 10.1182/Blood-2013-01-479972  0.44
2013 Figueroa ME, Chen SC, Andersson AK, Phillips LA, Li Y, Sotzen J, Kundu M, Downing JR, Melnick A, Mullighan CG. Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. The Journal of Clinical Investigation. 123: 3099-111. PMID 23921123 DOI: 10.1172/Jci66203  0.44
2013 Hatzi K, Jiang Y, Huang C, Garrett-Bakelman F, Gearhart MD, Giannopoulou EG, Zumbo P, Kirouac K, Bhaskara S, Polo JM, Kormaksson M, MacKerell AD, Xue F, Mason CE, Hiebert SW, ... ... Melnick A, et al. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell Reports. 4: 578-88. PMID 23911289 DOI: 10.1016/J.Celrep.2013.06.016  0.44
2013 Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Nowak D, Thoennissen GB, Rand V, Graeber TG, Koeffler HP, ... ... Melnick A, et al. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nature Medicine. 19: 1014-22. PMID 23852341 DOI: 10.1038/Nm.3247  0.44
2013 Santini V, Melnick A, Maciejewski JP, Duprez E, Nervi C, Cocco L, Ford KG, Mufti G. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Critical Reviews in Oncology/Hematology. 88: 231-45. PMID 23838480 DOI: 10.1016/J.Critrevonc.2013.06.004  0.44
2013 Sun XJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD, Chen WY, Tang Z, Nakadai T, Elemento O, Fischle W, Melnick A, Patel DJ, Nimer SD, Roeder RG. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature. 500: 93-7. PMID 23812588 DOI: 10.1038/Nature12287  0.44
2013 Bertolo C, Roa S, Sagardoy A, Mena-Varas M, Robles EF, Martinez-Ferrandis JI, Sagaert X, Tousseyn T, Orta A, Lossos IS, Amar S, Natkunam Y, Briones J, Melnick A, Malumbres R, et al. LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas. British Journal of Haematology. 162: 621-30. PMID 23795761 DOI: 10.1111/Bjh.12440  0.44
2013 Li S, Garrett-Bakelman FE, Akalin A, Zumbo P, Levine R, To BL, Lewis ID, Brown AL, D'Andrea RJ, Melnick A, Mason CE. An optimized algorithm for detecting and annotating regional differential methylation. Bmc Bioinformatics. 14: S10. PMID 23735126 DOI: 10.1186/1471-2105-14-S5-S10  0.44
2013 Bunting KL, Melnick AM. New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes Current Opinion in Immunology. 25: 339-346. PMID 23725655 DOI: 10.1016/j.coi.2013.05.003  0.44
2013 Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK, McCabe MT, ... ... Melnick AM, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 23: 677-92. PMID 23680150 DOI: 10.1016/J.Ccr.2013.04.011  0.44
2013 Fontan L, Melnick A. Discovering what makes STAT signaling TYK in T-ALL Cancer Discovery. 3: 494-496. PMID 23658297 DOI: 10.1158/2159-8290.Cd-13-0123  0.44
2013 Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 121: 5192-202. PMID 23632889 DOI: 10.1182/Blood-2013-03-490763  0.44
2013 Sagardoy A, Martinez-Ferrandis JI, Roa S, Bunting KL, Aznar MA, Elemento O, Shaknovich R, Fontán L, Fresquet V, Perez-Roger I, Robles EF, De Smedt L, Sagaert X, Melnick A, Martinez-Climent JA. Downregulation of FOXP1 is required during germinal center B-cell function. Blood. 121: 4311-20. PMID 23580662 DOI: 10.1182/Blood-2012-10-462846  0.44
2013 Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, et al. Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. Nature Immunology. 14: 437-45. PMID 23563689 DOI: 10.1038/Ni.2572  0.44
2013 Lu Z, Tsai AG, Akasaka T, Ohno H, Jiang Y, Melnick AM, Greisman HA, Lieber MR. BCL6 breaks occur at different AID sequence motifs in Ig-BCL6 and non-Ig-BCL6 rearrangements. Blood. 121: 4551-4. PMID 23476051 DOI: 10.1182/Blood-2012-10-464958  0.44
2013 Huang C, Hatzi K, Melnick A. Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms Nature Immunology. 14: 380-388. PMID 23455674 DOI: 10.1038/Ni.2543  0.44
2013 Kannan S, Sutphin RM, Hall MG, Golfman LS, Fang W, Nolo RM, Akers LJ, Hammitt RA, McMurray JS, Kornblau SM, Melnick AM, Figueroa ME, Zweidler-McKay PA. Notch activation inhibits AML growth and survival: a potential therapeutic approach. The Journal of Experimental Medicine. 210: 321-37. PMID 23359069 DOI: 10.1084/jem.20121527  0.44
2013 Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, Biswas D, Roeder RG, Allis CD, Melnick A, de Bruijn MF, Milne TA. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Reports. 3: 116-27. PMID 23352661 DOI: 10.1016/J.Celrep.2012.12.016  0.44
2013 Oh JE, Chambwe N, Klein S, Gal J, Andrews S, Gleason G, Shaknovich R, Melnick A, Campagne F, Toth M. Differential gene body methylation and reduced expression of cell adhesion and neurotransmitter receptor genes in adverse maternal environment. Translational Psychiatry. 3: e218. PMID 23340501 DOI: 10.1038/tp.2012.130  0.44
2013 De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM, Cerchietti L, Gascoyne RD, Melnick A, Michor F. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. Plos Genetics. 9: e1003137. PMID 23326238 DOI: 10.1371/Journal.Pgen.1003137  0.44
2013 Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJM, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML Leukemia. 27: 852-860. PMID 23235717 DOI: 10.1038/Leu.2012.363  0.44
2013 Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H, Melnick AM, Elemento O, Demichelis F, Rubin MA. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Research. 73: 1232-44. PMID 23233736 DOI: 10.1158/0008-5472.Can-12-2968  0.44
2013 Ramezani-Rad P, Geng H, Hurtz C, Chan LN, Chen Z, Jumaa H, Melnick A, Paietta E, Carroll WL, Willman CL, Lefebvre V, Müschen M. SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood. 121: 148-55. PMID 23152540 DOI: 10.1182/Blood-2012-05-428938  0.44
2013 Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat TD, Sohal D, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski JP, Melnick AM, Greally JM, et al. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. Cancer Research. 73: 1076-85. PMID 23066032 DOI: 10.1158/0008-5472.Can-12-0735  0.44
2013 Park-Min KH, Lee EY, Moskowitz NK, Lim E, Lee SK, Lorenzo JA, Huang C, Melnick AM, Purdue PE, Goldring SR, Ivashkiv LB. Negative regulation of osteoclast precursor differentiation by CD11b and β2 integrin-B-cell lymphoma 6 signaling. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 135-49. PMID 22893614 DOI: 10.1002/Jbmr.1739  0.44
2013 Teater MR, Hatzi K, Popovich R, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Chung YR, Shaknovich R, Creasy C, Gascoyne RD, Cerchietti L, Levine RL, Abdel-Wahab O, ... ... Melnick AM, et al. EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains Blood. 122: 1-1. DOI: 10.1182/Blood.V122.21.1.1  0.8
2013 Garrett-Bakelman FE, Melnick AM. Differentiation therapy for IDH1/2 mutant malignancies Cell Research. 23: 975-977. DOI: 10.1038/cr.2013.73  0.44
2012 Fontan L, Melnick A. Targeting lymphomas through MALT1 inhibition Oncotarget. 3: 1493-1494. PMID 23455603 DOI: 10.18632/Oncotarget.819  0.44
2012 Polo JM, Anderssen E, Walsh RM, Schwarz BA, Nefzger CM, Lim SM, Borkent M, Apostolou E, Alaei S, Cloutier J, Bar-Nur O, Cheloufi S, Stadtfeld M, Figueroa ME, Robinton D, ... ... Melnick A, et al. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell. 151: 1617-32. PMID 23260147 DOI: 10.1016/J.Cell.2012.11.039  0.44
2012 Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SN, Fang F, Gascoyne RD, Martinez-Climent JA, Glickman JF, Borden K, ... ... Melnick A, et al. MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo Cancer Cell. 22: 812-824. PMID 23238016 DOI: 10.1016/J.Ccr.2012.11.003  0.44
2012 Alberich-Jordà M, Wouters B, Balastik M, Shapiro-Koss C, Zhang H, Di Ruscio A, DiRuscio A, Radomska HS, Ebralidze AK, Amabile G, Ye M, Zhang J, Lowers I, Avellino R, Melnick A, et al. C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia. The Journal of Clinical Investigation. 122: 4490-504. PMID 23160200 DOI: 10.1172/Jci65102  0.44
2012 Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, ... ... Melnick AM, et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discovery. 2: 1004-23. PMID 23107779 DOI: 10.1158/2159-8290.Cd-12-0208  0.44
2012 Akalin A, Kormaksson M, Li S, Garrett-Bakelman FE, Figueroa ME, Melnick A, Mason CE. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biology. 13: R87. PMID 23034086 DOI: 10.1186/Gb-2012-13-10-R87  0.44
2012 Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, Mollica L, Li J, Viale A, Heguy A, Hassimi M, Socci N, Bhatt PK, Gonen M, Mason CE, ... Melnick A, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics. 44: 1179-81. PMID 23001125 DOI: 10.1038/Ng.2413  0.44
2012 Ouillette P, Li J, Shaknovich R, Li Y, Melnick A, Shedden K, Malek SN. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes, Chromosomes & Cancer. 51: 1125-32. PMID 22952040 DOI: 10.1002/Gcc.21997  0.44
2012 Kawahara M, Pandolfi A, Bartholdy B, Barreyro L, Will B, Roth M, Okoye-Okafor UC, Todorova TI, Figueroa ME, Melnick A, Mitsiades CS, Steidl U. H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. Cancer Cell. 22: 194-208. PMID 22897850 DOI: 10.1016/J.Ccr.2012.06.027  0.44
2012 Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, Perna F, Zhao X, Taylor JE, Park CY, Carroll M, ... Melnick A, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 22: 180-93. PMID 22897849 DOI: 10.1016/J.Ccr.2012.06.032  0.44
2012 Gönen M, Sun Z, Figueroa ME, Patel JP, Abdel-Wahab O, Racevskis J, Ketterling RP, Fernandez H, Rowe JM, Tallman MS, Melnick A, Levine RL, Paietta E. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 120: 2297-306. PMID 22855599 DOI: 10.1182/Blood-2012-02-414425  0.44
2012 Jiang Y, Soong TD, Wang L, Melnick AM, Elemento O. Genome-wide detection of genes targeted by Non-Ig somatic hypermutation in lymphoma Plos One. 7. PMID 22808135 DOI: 10.1371/Journal.Pone.0040332  0.44
2012 Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brüstle A, Harris IS, Holmes R, Wakeham A, Haight J, You-Ten A, Li WY, Schalm S, Su SM, Virtanen C, ... ... Melnick A, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 488: 656-9. PMID 22763442 DOI: 10.1038/Nature11323  0.44
2012 Akalin A, Garrett-Bakelman FE, Kormaksson M, Busuttil J, Zhang L, Khrebtukova I, Milne TA, Huang Y, Biswas D, Hess JL, Allis CD, Roeder RG, Valk PJ, Löwenberg B, Delwel R, ... ... Melnick A, et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. Plos Genetics. 8: e1002781. PMID 22737091 DOI: 10.1371/Journal.Pgen.1002781  0.44
2012 Rickman DS, Soong TD, Moss B, Mosquera JM, Dlabal J, Terry S, MacDonald TY, Tripodi J, Bunting K, Najfeld V, Demichelis F, Melnick AM, Elemento O, Rubin MA. Oncogene-mediated alterations in chromatin conformation Proceedings of the National Academy of Sciences of the United States of America. 109: 9083-9088. PMID 22615383 DOI: 10.1073/pnas.1112570109  0.44
2012 Cubedo E, Gentles AJ, Huang C, Natkunam Y, Bhatt S, Lu X, Jiang X, Romero-Camarero I, Freud A, Zhao S, Bacchi CE, Martínez-Climent JA, Sánchez-García I, Melnick A, Lossos IS. Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. Blood. 119: 5478-91. PMID 22517897 DOI: 10.1182/Blood-2012-01-403154  0.44
2012 Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, Abbas S, Figueroa ME, Zeilemaker A, Melnick A, Löwenberg B, Valk PJ, Delwel R. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood. 119: 5824-31. PMID 22490330 DOI: 10.1182/Blood-2011-07-367961  0.44
2012 Barish GD, Yu RT, Karunasiri MS, Becerra D, Kim J, Tseng TW, Tai LJ, Leblanc M, Diehl C, Cerchietti L, Miller YI, Witztum JL, Melnick AM, Dent AL, Tangirala RK, et al. The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. Cell Metabolism. 15: 554-62. PMID 22465074 DOI: 10.1016/J.Cmet.2012.02.012  0.44
2012 Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, ... ... Melnick A, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. The New England Journal of Medicine. 366: 1079-89. PMID 22417203 DOI: 10.1056/Nejmoa1112304  0.44
2012 Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 483: 474-8. PMID 22343901 DOI: 10.1038/Nature10860  0.44
2012 Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, Bhattacharya S, Zehnder J, Liedtke M, Gotlib JR, Coutre S, Berube C, Melnick A, Levine R, Mitchell BS, et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 26: 893-901. PMID 22033493 DOI: 10.1038/Leu.2011.294  0.44
2012 Kormaksson M, Booth JG, Figueroa ME, Melnick A. Integrative model-based clustering of microarray methylation and expression data Annals of Applied Statistics. 6: 1327-1347. DOI: 10.1214/11-Aoas533  0.44
2012 Melnick A. Epigenetic Therapy Leaps Ahead with Specific Targeting of EZH2 Cancer Cell. 22: 569-570. DOI: 10.1016/j.ccr.2012.10.016  0.44
2011 Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, Socci ND, Teruya-Feldstein J, Weis-Garcia F, Tam W, Shaknovich R, ... Melnick A, et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell. 147: 554-64. PMID 22036564 DOI: 10.1016/J.Cell.2011.09.035  0.44
2011 Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, Pandey A, Melnick AM, Sinha U, Wang YL. SYK inhibition and response prediction in diffuse large B-cell lymphoma Blood. 118: 6342-6352. PMID 22025527 DOI: 10.1182/blood-2011-02-333773  0.44
2011 Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, ... ... Melnick A, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature Chemical Biology. 7: 818-26. PMID 21946277 DOI: 10.1038/Nchembio.670  0.44
2011 Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, ... ... Melnick AM, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. The Journal of Experimental Medicine. 208: 2163-74. PMID 21911423 DOI: 10.1084/Jem.20110304  0.44
2011 Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, Ye BH, Melnick A, Müschen M. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood. 118: 4174-8. PMID 21856866 DOI: 10.1182/Blood-2011-01-331181  0.44
2011 Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SN, Weinhold N, Reimers M, Clozel T, Luttrop K, Ekstrom TJ, Frank J, Vasanthakumar A, ... ... Melnick A, et al. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood. 118: 3559-69. PMID 21828137 DOI: 10.1182/Blood-2011-06-357996  0.44
2011 Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H, Asai T, Xu H, Deblasio T, Menendez S, Voza F, ... ... Melnick A, et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science (New York, N.Y.). 333: 765-9. PMID 21764752 DOI: 10.1126/Science.1201662  0.44
2011 Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa ME, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, ... ... Melnick A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 20: 11-24. PMID 21723200 DOI: 10.1016/J.Ccr.2011.06.001  0.44
2011 Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, ... ... Melnick A, et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 473: 384-8. PMID 21593872 DOI: 10.1038/Nature09883  0.44
2011 Shaknovich R, Melnick A. Epigenetics and B-cell lymphoma Current Opinion in Hematology. 18: 293-299. PMID 21577103 DOI: 10.1097/Moh.0B013E32834788Cf  0.44
2011 Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kambhampati S, Parmar S, Nischal S, Hueck C, ... ... Melnick A, et al. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. The Journal of Biological Chemistry. 286: 25211-23. PMID 21532034 DOI: 10.1074/Jbc.M111.235028  0.44
2011 Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C, Yang SN, Reiter A, Siebert R, Melnick A, Woessmann W. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. Plos One. 6: e18436. PMID 21494621 DOI: 10.1371/Journal.Pone.0018436  0.44
2011 Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari MJ, Yu Y, Montagna C, Montgomery EA, Canto M, Dunbar KB, Wang J, Roa JC, Mo Y, Bhagat T, Ramesh KH, ... ... Melnick A, et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. Plos Genetics. 7: e1001356. PMID 21483804 DOI: 10.1371/Journal.Pgen.1001356  0.44
2011 Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, Nicolas C, Payer AR, Fernandez HF, Tallman MS, Paietta E, Melnick A, Vandenberghe P, Speleman F, Aifantis I, et al. PHF6 mutations in adult acute myeloid leukemia Leukemia. 25: 130-134. PMID 21030981 DOI: 10.1038/Leu.2010.247  0.44
2011 Lugthart S, Figueroa ME, Bindels E, Skrabanek L, Valk PJ, Li Y, Meyer S, Erpelinck-Verschueren C, Greally J, Löwenberg B, Melnick A, Delwel R. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood. 117: 234-41. PMID 20855866 DOI: 10.1182/Blood-2010-04-281337  0.44
2010 Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, ... ... Melnick A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 18: 553-67. PMID 21130701 DOI: 10.1016/J.Ccr.2010.11.015  0.44
2010 Melnick AM. Epigenetics in AML Best Practice and Research: Clinical Haematology. 23: 463-468. PMID 21130408 DOI: 10.1016/j.beha.2010.09.017  0.44
2010 Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. The Journal of Clinical Investigation. 120: 4569-82. PMID 21041953 DOI: 10.1172/Jci42869  0.44
2010 Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, Elemento O. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood. 116: 5247-55. PMID 20736451 DOI: 10.1182/blood-2010-04-280149  0.44
2010 Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, Apostolou E, Stadtfeld M, Li Y, Shioda T, Natesan S, Wagers AJ, Melnick A, Evans T, Hochedlinger K. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nature Biotechnology. 28: 848-55. PMID 20644536 DOI: 10.1038/Nbt.1667  0.44
2010 Murphy MW, Sarver AL, Rice D, Hatzi K, Ye K, Melnick A, Heckert LL, Zarkower D, Bardwell VJ. Genome-wide analysis of DNA binding and transcriptional regulation by the mammalian Doublesex homolog DMRT1 in the juvenile testis. Proceedings of the National Academy of Sciences of the United States of America. 107: 13360-5. PMID 20616082 DOI: 10.1073/Pnas.1006243107  0.44
2010 Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, Gascoyne RD, Elemento O, Melnick A. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood. 116: e81-9. PMID 20610814 DOI: 10.1182/Blood-2010-05-285320  0.44
2010 Shah MY, Vasanthakumar A, Barnes NY, Figueroa ME, Kamp A, Hendrick C, Ostler KR, Davis EM, Lin S, Anastasi J, Le Beau MM, Moskowitz IP, Melnick A, Pytel P, Godley LA. DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Research. 70: 5840-50. PMID 20587527 DOI: 10.1158/0008-5472.CAN-10-0847  0.44
2010 Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clinical Lymphoma, Myeloma & Leukemia. 10: 192-6. PMID 20511164 DOI: 10.3816/Clml.2010.N.030  0.44
2010 Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jäck HM, Hurtz C, Ramezani-Rad P, Herzog S, ... ... Melnick AM, et al. BCL6 is critical for the development of a diverse primary B cell repertoire. The Journal of Experimental Medicine. 207: 1209-21. PMID 20498019 DOI: 10.1084/Jem.20091299  0.44
2010 Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh KS, Goy A, Wilson W, Verma A, Braunschweig I, ... ... Melnick A, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood. 116: 1025-34. PMID 20427703 DOI: 10.1182/Blood-2009-12-257485  0.44
2010 Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Farès C, Arrowsmith CH, Yang SN, Garcia M, Coop A, Mackerell AD, Privé GG, ... Melnick A, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 17: 400-11. PMID 20385364 DOI: 10.1016/J.Ccr.2009.12.050  0.36
2010 Winter JN, Li S, Aurora V, Variakojis D, Nelson B, Krajewska M, Zhang L, Habermann TM, Fisher RI, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, ... ... Melnick A, et al. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2435-42. PMID 20371683 DOI: 10.1158/1078-0432.Ccr-09-1219  0.44
2010 Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 709-28. PMID 20227509 DOI: 10.1016/J.Bbmt.2010.03.002  0.44
2010 Shaknovich R, Figueroa ME, Melnick A. HELP (HpaII tiny fragment enrichment by ligation-mediated PCR) assay for DNA methylation profiling of primary normal and malignant B lymphocytes. Methods in Molecular Biology (Clifton, N.J.). 632: 191-201. PMID 20217579 DOI: 10.1007/978-1-60761-663-4_12  0.44
2010 Schafer E, Irizarry R, Negi S, McIntyre E, Small D, Figueroa ME, Melnick A, Brown P. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood. 115: 4798-809. PMID 20215641 DOI: 10.1182/Blood-2009-09-243634  0.44
2010 Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Greally JM, Valk PJ, Löwenberg B, ... ... Melnick A, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 17: 13-27. PMID 20060365 DOI: 10.1016/J.Ccr.2009.11.020  0.44
2010 Hammerich-Hille S, Kaipparettu BA, Tsimelzon A, Creighton CJ, Jiang S, Polo JM, Melnick A, Meyer R, Oesterreich S. SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells. The Journal of Biological Chemistry. 285: 3608-16. PMID 19901029 DOI: 10.1074/Jbc.M109.066431  0.44
2009 Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nature Medicine. 15: 1369-76. PMID 19966776 DOI: 10.1038/Nm.2059  0.44
2009 Juszczynski P, Chen L, O'Donnell E, Polo JM, Ranuncolo SM, Dalla-Favera R, Melnick A, Shipp MA. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood. 114: 5315-21. PMID 19855081 DOI: 10.1182/Blood-2009-02-204362  0.44
2009 Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, Fernandez H, Tallman MS, Greally JM, Carraway H, Licht JD, Gore SD, Melnick A. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 114: 3448-58. PMID 19652201 DOI: 10.1182/Blood-2009-01-200519  0.44
2009 Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, ... ... Melnick A, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences of the United States of America. 106: 8368-73. PMID 19416831 DOI: 10.1073/Pnas.0903392106  0.44
2009 Oda M, Glass JL, Thompson RF, Mo Y, Olivier EN, Figueroa ME, Selzer RR, Richmond TA, Zhang X, Dannenberg L, Green RD, Melnick A, Hatchwell E, Bouhassira EE, Verma A, et al. High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Research. 37: 3829-39. PMID 19386619 DOI: 10.1093/Nar/Gkp260  0.44
2009 Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN, Ye K, Farinha P, Horsman DE, Gascoyne RD, Elemento O, Melnick A. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood. 113: 5536-48. PMID 19307668 DOI: 10.1182/Blood-2008-12-193037  0.44
2009 Figueroa ME, Melnick A, Greally JM. Genome-wide determination of DNA methylation by Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) for the study of acute leukemias. Methods in Molecular Biology (Clifton, N.J.). 538: 395-407. PMID 19277580 DOI: 10.1007/978-1-59745-418-6_20  0.44
2009 Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1209-13. PMID 19188674 DOI: 10.1200/Jco.2008.19.6121  0.44
2009 Figueroa ME, Wouters BJ, Skrabanek L, Glass J, Li Y, Erpelinck-Verschueren CA, Langerak AW, Löwenberg B, Fazzari M, Greally JM, Valk PJ, Melnick A, Delwel R. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood. 113: 2795-804. PMID 19168792 DOI: 10.1182/Blood-2008-08-172387  0.44
2009 Laurenzana A, Petruccelli LA, Pettersson F, Figueroa ME, Melnick A, Baldwin AS, Paoletti F, Miller WH. Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. Cancer Research. 69: 55-64. PMID 19117987 DOI: 10.1158/0008-5472.Can-08-0245  0.44
2009 Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood. 113: 3397-405. PMID 18927431 DOI: 10.1182/Blood-2008-07-168773  0.44
2009 Duy C, Yu JJ, Swaminathan S, Nahar RR, Kweon S, Polo JM, Valls E, Klemm L, Cerchietti L, Levetzow Gv, Herzog S, Jumaa H, Alborán IMd, Melnick A, Ye BH, et al. BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire. Blood. 114: 91-91. DOI: 10.1182/Blood.V114.22.91.91  0.36
2009 Duy C, Cerchietti L, Yu JJ, Ci W, Swaminathan S, Nahar RR, Kweon S, Klemm L, Ye BH, Melnick A, Müschen M. BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia. Blood. 114: 765-765. DOI: 10.1182/Blood.V114.22.765.765  0.36
2009 Hurtz C, Duy C, Cerchietti L, Park E, Ci W, Swaminathan S, Kweon S, Klemm L, Kim Y, Martinelli G, Hofmann W, Ye BH, Melnick A, Müschen M. BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia. Blood. 114: 2167-2167. DOI: 10.1182/Blood.V114.22.2167.2167  0.36
2008 Melnick A. Transitioning from fellowship to a physician-scientist career track Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 16-22. PMID 19074048 DOI: 10.1182/Asheducation-2008.1.16  0.44
2008 Lopes EC, Valls E, Figueroa ME, Mazur A, Meng FG, Chiosis G, Laird PW, Schreiber-Agus N, Greally JM, Prokhortchouk E, Melnick A. Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. Cancer Research. 68: 7258-63. PMID 18794111 DOI: 10.1158/0008-5472.Can-08-0344  0.44
2008 Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mo Y, Bhagat T, Mariadason J, Boultwood J, Melnick A, Greally J, Verma A. Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration. Plos One. 3: e2965. PMID 18698424 DOI: 10.1371/Journal.Pone.0002965  0.44
2008 Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao GD, Augenlicht LH, Mariadason JM. HDAC4 promotes growth of colon cancer cells via repression of p21. Molecular Biology of the Cell. 19: 4062-75. PMID 18632985 DOI: 10.1091/Mbc.E08-02-0139  0.44
2008 Ci W, Polo JM, Melnick A. B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Current Opinion in Hematology. 15: 381-390. PMID 18536578 DOI: 10.1097/Moh.0B013E328302C7Df  0.36
2008 Ranuncolo SM, Wang L, Polo JM, Dell'Oso T, Dierov J, Gaymes TJ, Rassool F, Carroll M, Melnick A. BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner Journal of Biological Chemistry. 283: 22565-22572. PMID 18524763 DOI: 10.1074/Jbc.M803490200  0.44
2008 Polo JM, Ci W, Licht JD, Melnick A. Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells Blood. 112: 644-651. PMID 18487509 DOI: 10.1182/Blood-2008-01-131813  0.44
2008 Parekh S, Prive G, Melnick A. Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas Leukemia and Lymphoma. 49: 874-882. PMID 18452090 DOI: 10.1080/10428190801895345  0.44
2008 Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A. Sequential transcription factor targeting for diffuse large B-cell lymphomas. Cancer Research. 68: 3361-9. PMID 18451163 DOI: 10.1158/0008-5472.Can-07-5817  0.44
2008 Figueroa ME, Reimers M, Thompson RF, Ye K, Li Y, Selzer RR, Fridriksson J, Paietta E, Wiernik P, Green RD, Greally JM, Melnick A. An integrative genomic and epigenomic approach for the study of transcriptional regulation. Plos One. 3: e1882. PMID 18365023 DOI: 10.1371/Journal.Pone.0001882  0.44
2008 Ranuncolo SM, Polo JM, Melnick A. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. Blood Cells Molecules and Diseases. 41: 95-99. PMID 18346918 DOI: 10.1016/J.Bcmd.2008.02.003  0.36
2008 Mendez LM, Polo JM, Yu JJ, Krupski M, Ding BB, Melnick A, Ye BH. CtBP is an essential corepressor for BCL6 autoregulation. Molecular and Cellular Biology. 28: 2175-86. PMID 18212045 DOI: 10.1128/Mcb.01400-07  0.36
2007 Glass JL, Thompson RF, Khulan B, Figueroa ME, Olivier EN, Oakley EJ, Van Zant G, Bouhassira EE, Melnick A, Golden A, Fazzari MJ, Greally JM. CG dinucleotide clustering is a species-specific property of the genome. Nucleic Acids Research. 35: 6798-807. PMID 17932072 DOI: 10.1093/Nar/Gkm489  0.44
2007 Parekh S, Polo JM, Shaknovich R, Juszczynski P, Lev P, Ranuncolo SM, Yin Y, Klein U, Cattoretti G, Dalla Favera R, Shipp MA, Melnick A. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood. 110: 2067-74. PMID 17545502 DOI: 10.1182/Blood-2007-01-069575  0.36
2007 Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, Shipp M, Melnick A. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 104: 3207-12. PMID 17360630 DOI: 10.1073/Pnas.0611399104  0.36
2007 Ci W, Polo JM, Ranuncolo SM, Melnick A. A “Survival of the Fittest” Mechanism for Weeding Out Potentially Lymphomagenic B-Cells during Germinal Center B-Cell Differentiation. Blood. 110: 559-559. DOI: 10.1182/Blood.V110.11.559.559  0.36
2007 Polo JM, Chatzi K, Dell’Oso T, Lev P, Melnick A. BCL6 Transcriptionally Reprograms the DLBCL Genome by Forming Distinct Biochemically Active Complexes on Genes Corresponding to Different Pathways. Blood. 110: 2646-2646. DOI: 10.1182/Blood.V110.11.2646.2646  0.36
2006 Khulan B, Thompson RF, Ye K, Fazzari MJ, Suzuki M, Stasiek E, Figueroa ME, Glass JL, Chen Q, Montagna C, Hatchwell E, Selzer RR, Richmond TA, Green RD, Melnick A, et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Research. 16: 1046-55. PMID 16809668 DOI: 10.1101/Gr.5273806  0.44
2005 Melnick AM, Adelson K, Licht JD. The theoretical basis of transcriptional therapy of cancer: can it be put into practice? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3957-70. PMID 15867201 DOI: 10.1200/JCO.2005.14.498  0.8
2004 Polo JM, Dell'Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD, Melnick A. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nature Medicine. 10: 1329-35. PMID 15531890 DOI: 10.1038/Nm1134  0.8
2004 Takahashi S, McConnell MJ, Harigae H, Kaku M, Sasaki T, Melnick AM, Licht JD. The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood. 103: 4650-8. PMID 14982881 DOI: 10.1182/blood-2003-08-2759  0.44
2004 Chevallier N, Corcoran CM, Lennon C, Hyjek E, Chadburn A, Bardwell VJ, Licht JD, Melnick A. ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood. 103: 1454-63. PMID 14551142 DOI: 10.1182/Blood-2003-06-2081  0.44
2004 Polo JM, Dell’Oso T, Ranuncolo SM, Cerchietti L, Silva GFD, Prive GG, Licht JD, Melnick A. Specific Peptide Disruption of the Bcl-6 Repression Complex Reveals Its Transcriptional Mechanism of Action in Normal and Malignant B-Cells and Is a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma. Blood. 104: 5-5. DOI: 10.1182/Blood.V104.11.5.5  0.8
2003 Ahmad KF, Melnick A, Lax S, Bouchard D, Liu J, Kiang CL, Mayer S, Takahashi S, Licht JD, Privé GG. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Molecular Cell. 12: 1551-64. PMID 14690607 DOI: 10.1016/S1097-2765(03)00454-4  0.8
2003 Sirulnik A, Melnick A, Zelent A, Licht JD. Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Practice & Research. Clinical Haematology. 16: 387-408. PMID 12935958 DOI: 10.1016/S1521-6926(03)00062-8  0.8
2002 Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Current Opinion in Hematology. 9: 322-32. PMID 12042707 DOI: 10.1097/00062752-200207000-00010  0.8
2002 Walker RH, Morgello S, Davidoff-Feldman B, Melnick A, Walsh MJ, Shashidharan P, Brin MF. Autosomal dominant chorea-acanthocytosis with polyglutamine-containing neuronal inclusions. Neurology. 58: 1031-7. PMID 11940688 DOI: 10.1212/Wnl.58.7.1031  0.44
2002 Melnick A, Carlile G, Ahmad KF, Kiang CL, Corcoran C, Bardwell V, Prive GG, Licht JD. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Molecular and Cellular Biology. 22: 1804-18. PMID 11865059 DOI: 10.1128/Mcb.22.6.1804-1818.2002  0.8
2001 Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene. 20: 7186-7203. PMID 11704847 DOI: 10.1038/Sj.Onc.1204766  0.8
2000 Melnick A, Carlile GW, McConnell MJ, Polinger A, Hiebert SW, Licht JD. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood. 96: 3939-47. PMID 11090081 DOI: 10.1182/Blood.V96.12.3939.H8003939_3939_3947  0.44
2000 Melnick A, Ahmad KF, Arai S, Polinger A, Ball H, Borden KL, Carlile GW, Prive GG, Licht JD. In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions. Molecular and Cellular Biology. 20: 6550-67. PMID 10938130 DOI: 10.1128/Mcb.20.17.6550-6567.2000  0.44
2000 Melnick AM, Westendorf JJ, Polinger A, Carlile GW, Arai S, Ball HJ, Lutterbach B, Hiebert SW, Licht JD. The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein Molecular and Cellular Biology. 20: 2075-2086. PMID 10688654 DOI: 10.1128/Mcb.20.6.2075-2086.2000  0.44
2000 Melnick A, Westendorf J, Polinger A, Carlile G, Arai S, Ball H, Lutterbach B, Hiebert S, Licht J. Interaction between plzf and eto-a possible link in the molecular mechanisms of M2 and M3 leukemia Experimental Hematology. 28: 129-130. DOI: 10.1016/S0301-472X(00)00500-2  0.44
1999 Melnick A, Fruchtman S, Zelent A, Liu M, Huang Q, Boczkowska B, Calasanz MJ, Fernandez A, Licht JD, Najfeld V. Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21 Leukemia. 13: 1534-1538. PMID 10516754 DOI: 10.1038/Sj.Leu.2401513  0.44
1999 Ball HJ, Melnick A, Shaknovich R, Kohanski RA, Licht JD. The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase Nucleic Acids Research. 27: 4106-4113. PMID 10497277 DOI: 10.1093/Nar/27.20.4106  0.44
1999 Hoatlin ME, Zhi Y, Ball H, Silvey K, Melnick A, Stone S, Arai S, Hawe N, Owen G, Zelent A, Licht JD. A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF. Blood. 94: 3737-3747. DOI: 10.1182/Blood.V94.11.3737.423K39_3737_3747  0.8
1999 Melnick A, Licht JD. Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia Blood. 93: 3167-3215. DOI: 10.1182/Blood.V93.10.3167.410K44_3167_3215  0.8
1998 Shaknovich R, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S, Zelent AZ, Licht JD. The Promyelocytic Leukemia Zinc Finger Protein Affects Myeloid Cell Growth, Differentiation, and Apoptosis Molecular and Cellular Biology. 18: 5533-5545. PMID 9710637 DOI: 10.1128/Mcb.18.9.5533  0.8
Show low-probability matches.